HIV study tests which pill combo best shrinks the Virus's hideout
NCT ID NCT02987530
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested two different once-daily HIV medication combinations in 101 people who had just been infected with HIV-1. The goal was to see which combo better lowered the amount of hidden virus in immune cells after 48 weeks. Both treatments are standard HIV therapies, so this research aims to improve long-term disease control rather than cure the infection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV -1 INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hopital Bicetre
All the Regions of the Country (40 Centers), France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tracking HIV's genetic fingerprints reveal where the epidemic is heading?
- Can a new drug, GS-0415, help keep HIV in check? a First-in-Human trial aims to find out
- Could a shot replace daily HIV pills? new trial tests injectable combo
- Long-acting HIV shot studied in patients with severe kidney problems
- RNA vaccine aims to control HIV without daily pills
- Herbal formula may help HIV patients whose immune systems Don't fully recover